PLZ4-Coated Paclitaxel-Loaded Micelles for the Treatment of Patients With Recurrent or Refractory Non-Muscle Invasive Bladder Cancer

Summary

This phase I trial tests the safety, tolerability and effectiveness of PLZ4-coated paclitacel-loaded micelles (PPM) in treating patients with non-muscle invasive bladder cancer that has come back after a period of improvement (recurrent) or that does not respond to treatment (refractory). PPM is a bladder cancer-specific nanoparticle that can specifically target and deliver treatment to the tumor cells in the bladder. PPM contains paclitaxel, which is a drug that kills tumor cells or keeps them from growing.

Timeline

Start

2023-11-22

Primary completion

2026-12

Completion

2027-06

Publications

• Narayan A, Leibrandt RC, Lee JS, Dall'Era MA, Whitson JM, Chandrasekar T, Braun A, Mossanen M, Li H, Lara PN Jr, Lam KS, Pan CX, Parikh M. A Phase I trial of PLZ4-coated paclitaxel-loaded micelles in patients with refractory non-muscle-invasive bladder cancer. Nanomedicine (Lond). 2026 Jun;21(12):1707-1712. doi: 10.1080/17435889.2026.2674162. Epub 2026 Jun 1.

Drugs

Indications